This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pletz, M. W.
Right arrow Articles by Lode, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pletz, M. W.
Right arrow Articles by Lode, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2003, p. 1129-1131, Vol. 47, No. 3
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.3.1129-1131.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

ABT-773: Pharmacokinetics and Interactions with Ranitidine and Sucralfate

M. W. Pletz,1 V. Preechachatchaval,1 J. Bulitta,2 M. Allewelt,1 O. Burkhardt,1 and H. Lode1*

Department of Chest and Infectious Diseases, E. von Behring City Hospital, Free University of Berlin, Berlin,1 Institute for Biomedical and Pharmaceutical Research, Nuernberg-Heroldsberg, Germany2

Received 22 January 2002/ Returned for modification 24 May 2002/ Accepted 25 November 2002

We assessed the pharmacokinetics and interaction of ABT-773 in 12 volunteers receiving ABT-773 alone or concomitantly with ranitidine or sucralfate. Data for 150 mg of ABT-773 were as follows: the maximum concentration of the drug in plasma (Cmax) was 318 ng/ml, its half-life was 5.66 h, and its area under the plasma concentration-time curve from 0 h to {infty} (AUC0-{infty}) was 1,662 ng · h/ml. Coadministration of ranitidine, reduced the Cmax (-25.7%) and AUC0-{infty} (-15.8%) significantly. Sucralfate had no impact on the bioavailability of ABT-773.

* Corresponding author. Mailing address: Department of Chest and Infectious Diseases, Zentralklinik E. v. Behring/Dept. Lungenklinik Heckeskorn, Zum Heckeshorn 33, 14109 Berlin, Germany. Phone: 49 30 80022222. Fax: 49 30 80022623. E-mail: haloheck{at}zedat.fu-berlin.de.

Antimicrobial Agents and Chemotherapy, March 2003, p. 1129-1131, Vol. 47, No. 3
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.3.1129-1131.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Labro, M. T., Abdelghaffar, H., Babin-Chevaye, C. (2004). Interaction of the New Ketolide ABT-773 (Cethromycin) with Human Polymorphonuclear Neutrophils and the Phagocytic Cell Line PLB-985 In Vitro. Antimicrob. Agents Chemother. 48: 1096-1104 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»